Author:
Jiang Kuikui,Zhou Danyang,Xu Fei,Xia Wen,Zheng Qiufan,Lu Qianyi,Luo Rongzhen,Hong Ruoxi,Wang Shusen
Abstract
Abstract
Background
We aimed to identify the relationship between the genomic characteristics and clinical outcomes of oligo-metastatic breast cancer.
Methods
Oligo-metastatic breast cancer diagnosed by pathology from January 2001 and August 2019 were reviewed and we matched the poly-metastatic patients based on the clinicopathological features of patients included. Clinicopathological values and data of genomic alterations were collected. Oligo-recurrence (oligo-R) was defined as a situation where disease progression occurred in less than 5 anatomical sites and other anatomic areas still suppressed by the ongoing therapy.
Results
A total of 26 breast cancer patients were enrolled in our study, including 14 patients with strict oligo-metastatic disease (oligo-R > 6 months) and 12 with simultaneous poly-metastatic disease. PIK3CA, TP53 and ERBB2 were the most common shared alterations identified in patients included. Based on the median time of oligo-R, we divided the patients with oligo-metastasis into longer oligo-R group (oligo-R > 31.04 months) and shorter oligo-R group (oligo-R ≤ 31.04 months). The analysis of PIK3CA mutation sites showed that H1047R mutation was closely associated with oligo-metastasis, rather than poly-metastasis. H1047R mutation also predicted a better prognosis (oligo-R > 31.04 months) in oligo-metastatic breast cancer. In addition, HER2 positive was more likely to be related to a good outcome in patients with oligo-metastasis.
Conclusions
Through the genetic analysis of samples from oligo-metastasis, we found the prognostic values of PIK3CA H1047R and HER2 in oligo- and poly-metastasis. We improved the stratification of prognosis and provided new insights for biological behaviors of oligo-metastatic breast cancer.
Funder
Natural Science Foundation of Guangdong Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference57 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.
2. Huober J, Thürlimann B. The role of Combination Chemotherapy in the treatment of patients with metastatic breast Cancer. Breast Care (Basel). 2009;4:367–72. https://doi.org/10.1159/000262808.
3. Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). Breast (Edinburgh Scotland). 2018;39:131–8. https://doi.org/10.1016/j.breast.2018.03.002.
4. Bethesda MD, National Cancer Institute. SEER, Cancer Statistics, Review. 1975–2013 (2016). http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
5. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456–63. https://doi.org/10.1093/jnci/djq029.